Followers | 34 |
Posts | 2049 |
Boards Moderated | 0 |
Alias Born | 12/03/2013 |
Monday, June 30, 2014 11:10:46 AM
There was a dilution, but as far as we know it was done to strengthen the company's position for partnership negotiations and to help fund the growing R&D Department. This dilution was also a direct offering to "highly respected" biotech investors, per the CEO. That dilution has led to this short-term price hit but once the dust settles and final Phase 2a data is released followed by Phase 2b trial plans, I expect that those buying at these prices will be handsomely rewarded.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM